Does TOFACITINIB Cause Pulmonary fibrosis? 1,417 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 1,417 reports of Pulmonary fibrosis have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.9% of all adverse event reports for TOFACITINIB.
1,417
Reports of Pulmonary fibrosis with TOFACITINIB
0.9%
of all TOFACITINIB reports
529
Deaths
773
Hospitalizations
How Dangerous Is Pulmonary fibrosis From TOFACITINIB?
Of the 1,417 reports, 529 (37.3%) resulted in death, 773 (54.6%) required hospitalization, and 635 (44.8%) were considered life-threatening.
Is Pulmonary fibrosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 1,417 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Pulmonary fibrosis?
METHOTREXATE (2,912)
ADALIMUMAB (2,277)
RITUXIMAB (2,192)
ETANERCEPT (1,926)
TOCILIZUMAB (1,886)
ABATACEPT (1,828)
HYDROXYCHLOROQUINE (1,740)
LEFLUNOMIDE (1,731)
PREDNISONE (1,692)
INFLIXIMAB (1,595)
Which TOFACITINIB Alternatives Have Lower Pulmonary fibrosis Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN